We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS’ Opdivo Helped Esophageal, GEJ Cancer Patients Live Longer, Trial Finds
BMS’ Opdivo Helped Esophageal, GEJ Cancer Patients Live Longer, Trial Finds
Bristol Myers Squibb’s blockbuster cancer drug Opdivo (nivolumab) significantly extended the disease-free survival of esophageal/gastroesophageal junction (GEJ) cancer patients with residual pathologic disease when given as an adjuvant treatment, according to phase 3 trial findings.